<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768504</url>
  </required_header>
  <id_info>
    <org_study_id>CR2108KE</org_study_id>
    <nct_id>NCT04768504</nct_id>
  </id_info>
  <brief_title>Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study</brief_title>
  <official_title>An Open-label Study of Tofacitinib for the Treatment of Refractory Immune-related Colitis From checKpoint Inhibitor Therapy (TRICK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khashayar Esfahani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm pilot study evaluating the efficacy and safety of tofacitinib in cancer&#xD;
      patients with immune-related colitis from immune checkpoint inhibitor (ICI) therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective and endpoint&#xD;
&#xD;
      • Efficacy of tofacitinib in inducing clinical remission of immune related colitis, as&#xD;
      measured by the proportion of patients who experience diarrhea resolution to grade ≤1 as per&#xD;
      Common Terminology Criteria for Adverse Events [CTCAE] v5.0) without the requirement for&#xD;
      additional immunosuppression (e.g., corticosteroids, biologics, or other immunosuppressors&#xD;
      targeted for colitis) 8 weeks post-first dose of tofacitinib.&#xD;
&#xD;
      Secondary objectives and endpoints:&#xD;
&#xD;
        -  Safety of tofacitinib in cancer patients with immune-related colitis, as defined by the&#xD;
           occurrence of adverse events grade ≥3.&#xD;
&#xD;
        -  Efficacy of tofacitinib in cancer patients with immune colitis as defined by endoscopic&#xD;
           remission of colitis (a total Mayo score of ≤2) at 8 weeks.&#xD;
&#xD;
        -  Efficacy of tofacitinib to induce a clinical remission of immune-related colitis as&#xD;
           measured by the time, in days, necessary to achieve a diarrhea of grade ≤ 1 (as per&#xD;
           CTCAE v 5.0).&#xD;
&#xD;
        -  Number of patients with tumor progression at 8 weeks per iRECIST and RECIST 1.1 criteria&#xD;
           compared to baseline scans.&#xD;
&#xD;
      Exploratory objective&#xD;
&#xD;
      • The study will collect blood samples from participants seeking to characterize the&#xD;
      inflammatory landscape of ICI-mediated colitis and biomarkers predictive of response to&#xD;
      tofacitinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Remission of Diarrhea</measure>
    <time_frame>30 days</time_frame>
    <description>Resolution of diarrhea to grade 1 or less per Common Terminology Criteria for Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of tofacitinib</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as the occurrence of Grade 3 or higher adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>per Mayo score of less or equal than 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Immune-Mediated Colitis</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofacitinib 10 mg PO BID for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib 10 mg</intervention_name>
    <description>Tofacitinib 10 mg PO BID for 30 days</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Able to provide informed consent.&#xD;
&#xD;
          3. Exposure to an immune checkpoint inhibitor (CTLA-4, PD-1, PDL-1) as part of a cancer&#xD;
             treatment regimen within 6 months of the onset of colitis symptoms. The ICI may be&#xD;
             used as a single agent, or in combination with other ICIs, or with chemotherapy.&#xD;
&#xD;
          4. Current diagnosis of immune-related colitis characterized by grade ≥ 2 diarrhea as per&#xD;
             CTCAE v5.0.&#xD;
&#xD;
          5. Patients should have failed corticosteroids (at least 1mg/kg equivalent of prednisone&#xD;
             for a minimum of 72 hours), and at least one dose of a biologic agent (i.e. either a&#xD;
             TNFα inhibitor or an anti-integrin). Failure is defined as having ongoing grade ≥ 2&#xD;
             diarrhea per CTCAE v5.0.&#xD;
&#xD;
          6. Adequate hematological function, defined by:&#xD;
&#xD;
               1. hemoglobin ≥ 90 g/L&#xD;
&#xD;
               2. absolute neutrophil count ≥ 1.0 x 109/L&#xD;
&#xD;
               3. lymphocyte count ≥ 0.5 x 109/L&#xD;
&#xD;
               4. platelets ≥ 75 x 109/L&#xD;
&#xD;
               5. PT, PTT, INR ≤ 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
          7. Adequate liver function, as assessed by the Child Pugh classification score (appendix&#xD;
             1). Patients with scores A and B are eligible for enrollment. Patients with severe&#xD;
             hepatic impairment (Child Pugh C) are excluded from the study.&#xD;
&#xD;
          8. Adequate renal function as defined by an estimated clearance ≥ 40 mL/min, calculated&#xD;
             per the Cockroft-Gault formula (appendix 2).&#xD;
&#xD;
          9. Women of childbearing potential (WOCBP) are eligible if they agree to use adequate&#xD;
             contraception while on study.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients should meet none of the following exclusion criteria to be eligible for this&#xD;
        study:&#xD;
&#xD;
          1. Diagnosis of a thromboembolic event (deep vein thrombosis, pulmonary embolism, embolic&#xD;
             stroke, myocardial infarction, or peripheral arterial insufficiency) within 3 months&#xD;
             of enrollment.&#xD;
&#xD;
          2. Diagnosis of concomitant infectious colitis (e.g. C. Difficile or other bacterial&#xD;
             source), unless the patient has finished an appropriate length of treatment with&#xD;
             antibiotics as indicated for each diagnosis at the time of enrollment.&#xD;
&#xD;
          3. Any other grade ≥ 3 infection at the time of enrollment.&#xD;
&#xD;
          4. Prior therapy with a JAK inhibitor within 3 months preceding enrollment.&#xD;
&#xD;
          5. Active pregnancy or breastfeeding.&#xD;
&#xD;
          6. Patients on intravenous biologic agents for other baseline autoimmune conditions.&#xD;
&#xD;
          7. Patients having other concomitant uncontrolled irAEs at the time of enrollment which&#xD;
             would require systemic corticosteroids or biologic immunomodulatory agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khashayar Esfahani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Lambert, PhD</last_name>
    <phone>514-340-8222</phone>
    <email>clambert@jgh.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Mortimer B Davis Jewish General Hospital - CIUSSS Centre-Ouest</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faheem Khiyani</last_name>
      <phone>51434082222</phone>
      <phone_ext>24624</phone_ext>
      <email>faheem.khiyani.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527.</citation>
    <PMID>32521140</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Khashayar Esfahani</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Immune-related adverse events</keyword>
  <keyword>Immune-related colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

